Name: Josh Brown's "Best Stocks in the Market": Biotech
Uploaded: 2026-08-04T17:15:38+00:00
Duration: 383 s

Speakers

Josh Brown — CEO, Ritholtz Wealth Management

Halftime Report Panelist — Crypto Analyst, CoinDesk

Rob — Investment Committee Member

Halftime Report Panelist 2 — Crypto Analyst, CoinDesk

Scott Wapner — Host, CNBC

Summary

Josh Brown presents Incyte and Biogen as his 'Best Stocks in the Market,' citing strong earnings beats, expanding pipelines, and technical breakouts. The Halftime Report panel adds Eli Lilly, Vertex, Amgen, Gilead, and Bristol-Myers Squibb as their healthcare playbook, emphasizing rotation into biotech and cheap valuations.

Josh Brown highlights Incyte (INCY) after a big earnings beat and multi-drug pipeline expansion, with technical support around $109 and $101.
Brown also likes Biogen (BIIB) for its earnings beat and resistance at $218; a close above would confirm a breakout.
A panelist notes Incyte’s low analyst buy ratings (44%) and $128 price target as a contrarian bullish setup.
Eli Lilly (LLY) is seen as cheap and dominant in obesity, with upcoming drug approvals as catalysts.
Vertex (VRTX) was recently purchased as part of an increased healthcare allocation.
Rob recommends Amgen (AMGN) for its GLP-1 entry and cheap valuation, and Gilead (GILD) as an ignored name trading at 16x with strong franchises.
Another panelist favors Bristol-Myers Squibb (BMY) for its cheapness, dividend, and complementary pipeline, despite market skepticism on the potential AstraZeneca deal.
The broader theme is a rotation out of AI/tech into biotech, which is showing accumulation and strong fundamentals.

Ideas

Josh Brown CEO, Ritholtz Wealth Management 0:41

Earnings beat with expanding drug pipeline.

Incyte reported Q4 revenue of $1.67B and adjusted earnings of $3.09, crushing the $2.12 estimate, and raised full-year net sales guidance. The company, once seen as a one-drug name, now has a pipeline of 9–10 drugs in various stages of trials, all of which could be major winners. Technically, traders can watch the $109 area (50-day) as an alert, investors can use the 200-day near $101, with the uptrend over above $100.

Josh Brown CEO, Ritholtz Wealth Management 1:43

Earnings beat, breakout above $218 possible.

Biogen beat top- and bottom-line expectations with earnings coming in 18% above consensus and forward guidance raised. The stock has knocked on $218 multiple times; a clean close above that level would confirm a breakout. Traders can use $190 as support, investors can anchor to the 200-day at $183.

Josh Brown CEO, Ritholtz Wealth Management 2:31

Rotation into biotech under accumulation.

Money is rotating into biotech names that are working away from AI/capex and hyperscalers. These stocks are under accumulation again, putting up big numbers and bringing in new shareholders.

Halftime Report Panelist 2 Crypto Analyst, CoinDesk 4:08

Cheap, dividend, pipeline complements oncology.

Bristol-Myers Squibb is exceptionally cheap, has a good dividend yield, and possesses a pipeline that complements AstraZeneca’s oncology focus, particularly in cardiovascular, despite the negative market reaction to the rumored deal.

Rob Investment Committee Member 4:31

GLP-1 entry, pipeline, cheap, 3% yield.

Amgen has dominant franchises, is entering the GLP-1 space which offers upside, boasts one of the best pipelines in the business, is not expensive, and pays a 3% dividend yield.

Rob Investment Committee Member 4:31

Cheap, ignored, strong oncology and HIV.

Gilead is an ignored company, up only 8% year-to-date, trades at 16x earnings, has one of the best oncology franchises, and Biktarvy is the dominant HIV treatment.

Halftime Report Panelist Crypto Analyst, CoinDesk 5:03

Cheap valuation, dominant obesity franchise growth.

Eli Lilly has cheapened from its peak (P/E down from 50x to low 30s), is expected to deliver >30% revenue growth and 50% growth in its dominant obesity platform, and upcoming drug approvals could catalyze further upside.

Halftime Report Panelist Crypto Analyst, CoinDesk 6:02

New purchase as healthcare allocation increases.

Vertex was just purchased as the healthcare weighting was increased to 11.7%, reflecting a conviction that healthcare exposure should continue to rise.

Josh Brown's "Best Stocks in the Market": Biotech

Summary

Ideas

Up Next